Ranbaxy SWOT Analysis, USP & Competitors

Posted in Pharmaceuticals and Healthcare, Total Reads: 6201
Advertisements

SWOT Analysis of Ranbaxy with USP, Competition, STP (Segmentation, Targeting, Positioning) - Marketing Analysis

Ranbaxy

Parent Company

Ranbaxy

Category

Pharmaceuticals

Sector

Health care

Tagline/ Slogan

New boundaries, new Horizons; Trusted medicines healthier lives

USP

It is India’s largest pharmaceutical company

STP

Segment

Anti-Infectives, Cardiovascular & Diabetes, Dermatological, Neuro-Psychiatry, Pain management, Gastro-Intestinal, Nutritional

Target Group

Healthcare professionals, wholesalers, generic distributors, and hospitals

Positioning

A diversifies global healthcare company focused on patient’s needs

SWOT Analysis

Strengths

1.Top 10 Global Generic Company with a spread over 125 countries

2. over 13,000 well trained Employees, over 50 nationalities

3. Strong presence in the International market with a major share and a strong presence in India as well

4.It has operations in nearly 50 countries and has 7 manufacturing plants

Weaknesses

1. It is heavily dependent upon generics for its revenue generation

2. Constantly regulated policies by the govt means operational efficiency is affected

Opportunities

1.increasing health awareness

2.Improvement in distribution network & brand building

3. They can leverage  Synriam, anti-malarial drug in brand building

Threats

1.Increasingly stringent FDA Regulations

2.Exchange rate fluctuations

3.Global economic slowdown

Competition

Competitors

1. Sun Pharma Industries
2. Dr.Reddy's

3. Lupin

4. GlaxoSmithKline Pharmaceuticals Ltd



Advertisements



Looking for More Brands? Search BrandGuide

Edit the Brand or Add a New One : Contribute to BrandGuide

The brandnames and other brand information used in the brandguide section are properties of their respective companies. The companies are not associated with MBASkool in any way. The brand names are used purely for educational/academic purpose only.
Utmost Care has been taken in the analysis of the brands. However, if you find any ambiguity kindly help us improve.